Difference between revisions of "Team:Northwestern"
Jackarnold13 (Talk | contribs) |
|||
| (839 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
| − | {{ | + | {{Northwestern_Page_Head_temp}} |
| + | {{Navbar_temp}} | ||
| + | |||
<html> | <html> | ||
| − | < | + | <style> |
| + | p.big { | ||
| + | line-height: 1.8; | ||
| + | } | ||
| + | </style> | ||
| + | <head> | ||
| + | |||
| + | |||
<meta charset="UTF-8"> | <meta charset="UTF-8"> | ||
| + | <meta http-equiv="X-UA-Compatible" content="IE=edge"> | ||
| + | <meta name="viewport" content="width=device-width, initial-scale=1"> | ||
| + | <title>Home</title> | ||
| + | <!-- Bootstrap --> | ||
| + | <link rel="stylesheet" type="text/css" href="https://2017.igem.org/Template:Northwestern/CSS?action=raw&ctype=text/css" /> | ||
| − | < | + | <style> |
| − | + | .foo img:last-child{display:none} | |
| − | + | .foo:hover img:first-child{display:none} | |
| − | + | .foo:hover img:last-child{display:inline-block} | |
| + | } | ||
| + | /*h2 { | ||
| + | padding: 0; | ||
| + | font-weight: 300;*/ | ||
| + | } | ||
| + | h2 span { | ||
| + | margin-left: 1em; | ||
| + | color: #aaa; | ||
| + | font-size: 85%; | ||
| + | } | ||
| − | |||
| + | </style> | ||
| + | |||
| + | |||
| + | <style> | ||
| + | button{border: 0; background-color: #D3D3D3 | ||
| + | } | ||
| + | </style> | ||
| + | </head> | ||
| + | |||
| + | </style> | ||
| + | |||
| + | <script src="https://ajax.googleapis.com/ajax/libs/jquery/2.1.4/jquery.min.js"></script> | ||
| + | <script src="https://github.com/kswedberg/jquery-smooth-scroll/blob/master/jquery.smooth-scroll.min.js"></script> | ||
| + | <script> | ||
| + | $('.smooth').on('click', function() { | ||
| + | $.smoothScroll({ | ||
| + | scrollElement: $('body'), | ||
| + | scrollTarget: '#' + this.id | ||
| + | }); | ||
| + | |||
| + | return false; | ||
| + | }); | ||
| + | </script> | ||
<!-- First Parallax Image with Logo Text --> | <!-- First Parallax Image with Logo Text --> | ||
| − | <div class=" | + | <div class="w3-display-container w3-opacity-min" id="top"> |
| − | <div class=" | + | <div class="logo"> |
| − | + | ||
</div> | </div> | ||
| − | < | + | <div style="z-index:1 !important;" class="w3-display-bottommiddle w3-hide-medium w3-hide-small"> |
| + | <button style="position:relative !important; z-index:1 !important;" class="icon-button" onclick="window.location.href='#first'"> | ||
| + | <span style="color:#4C177D;" class="w3-xxxlarge glyphicon glyphicon-chevron-down"> | ||
| + | </span> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | ||
| − | + | ||
| − | + | </button> | |
| − | + | </div> | |
| − | </ | + | |
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
</div> | </div> | ||
| − | < | + | |
| − | <div class=" | + | <div class="bgimg-2 w3-display-container" id="first"> |
| − | <div class="w3-display- | + | <div style="padding: 5% 10%;"> |
| − | + | <h3 style="color:white" class="w3-center w3-padding-large"><br><br>Engineering pathways for integrating functional Cas9 protein into OMVs </h3><br> | |
| − | </div> | + | <p style="padding-right: 10%; padding-left:10%; font-size:14px; color:white;" class="big"> Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.<br><br> |
| + | </p> | ||
| + | |||
| + | <ul class="ch-grid" height="50%" style=padding:0;"> | ||
| + | <li> | ||
| + | <div class="ch-item ch-img-2"> | ||
| + | <div class="ch-info"> | ||
| + | <h3 class="ch-bubble">About us</h3> | ||
| + | <p class="ch-bubble">Northwestern University iGEM<br> | ||
| + | <a class="ch-bubble" href="https://2017.igem.org/Team:Northwestern/Team#">LEARN MORE</a></p> | ||
| + | </div> | ||
| + | </div> | ||
| + | </li> | ||
| + | <li> | ||
| + | <div class="ch-item ch-img-1"> | ||
| + | <div class="ch-info"> | ||
| + | <h3 class="ch-bubble">Project description</h3> | ||
| + | <p class="ch-bubble">Outer Membrane Vesicles<br> | ||
| + | <a class="ch-bubble" href="https://2017.igem.org/Team:Northwestern/project">LEARN MORE</a></p> | ||
| + | </div> | ||
| + | </div> | ||
| + | </li> | ||
| + | <li> | ||
| + | <div class="ch-item ch-img-3"> | ||
| + | <div class="ch-info"> | ||
| + | <h3 class="ch-bubble">Parts</h3> | ||
| + | <p class="ch-bubble">Cas9 fusion proteins<br> | ||
| + | <a class="ch-bubble" href="https://2017.igem.org/Team:Northwestern/Parts">LEARN MORE</a></p> | ||
| + | </div> | ||
| + | </div> | ||
| + | </li> | ||
| + | </ul> | ||
| + | |||
| + | |||
| + | </div> | ||
| + | <div style="z-index:1 !important;" class="w3-display-bottommiddle"> | ||
| + | <button height="80%" width="auto" style="position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small w3-hide-medium" onclick="scrollWin2()"> | ||
| + | <span style="color:white;" class="w3-xxxlarge glyphicon glyphicon-chevron-down"> | ||
| + | </span> | ||
| + | </button> | ||
| + | </div> | ||
</div> | </div> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | <div class="bgimg-3 w3-display-container" id="second"> | |
| − | + | <div style="padding: 5% 10%;"> | |
| − | + | <h3 style="black;" class="w3-center w3-padding-large"><br><br>Project significance</h3><br> | |
| + | <p style="padding-bottom:0; padding-right: 10%; padding-left:10%; black; font-size:14px;" class="big"> VesiCure aims to create a therapeutic delivery system for CRISPR gene-editing technology using bacterial outer-membrane vesicles (OMVs). We hope to be able to utilize this delivery system to target the antibiotic resistant genes in bacteria, thereby allowing antibiotic treatments to be effective by eliminating the adaptive ability of bacterial resistance. <b>By genetically altering the resistant bacteria, this treatment would help combat the problem of antibiotic resistance directly from the source</b>.<br><br> </p> | ||
| − | + | <figure> | |
| − | + | <br><br><br> | |
| − | + | <center><img src="https://static.igem.org/mediawiki/2017/c/c0/T--Northwestern--GlobePractices.png" width="350px" border="0"> | |
| + | </center></figure> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | <div style="z-index:1 !important;" class="w3-display-bottommiddle"> | |
| − | + | <button style="margin:0; padding:0; position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small w3-hide-medium" onclick="scrollWin3()"> | |
| − | < | + | <span style="color:black;" class="w3-xxxlarge glyphicon glyphicon-chevron-down"> |
| − | + | </span> | |
| − | </div> | + | </button> |
| + | </div></p> | ||
</div> | </div> | ||
| + | </div> | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | <div class="w3-display-container"> | ||
| + | <div> | ||
| + | <h3 class="w3-center w3-padding-large">Check out the video below to learn more about our project!</h3><br> | ||
| + | </div> | ||
| + | <div class="w3-center container"> | ||
| + | <span class="w3-center"> <video class="w3-center" controls><source src= "https://static.igem.org/mediawiki/2017/6/60/T--Northwestern--videofast.mp4" type="video/mp4" type="video/mp4"></video> </span> | ||
| + | </div> | ||
| + | </div> | ||
| + | <!-- Hide this text on small devices --> | ||
| + | </div> | ||
| + | |||
| + | <!-- Container (Team Section) --> | ||
| + | |||
| + | <!-- Responsive Grid. Four columns on tablets, laptops and desktops. Will stack on mobile devices/small screens (100% width) | ||
| + | |||
| + | |||
<!-- Modal for full size images on click--> | <!-- Modal for full size images on click--> | ||
| Line 132: | Line 175: | ||
</div> | </div> | ||
</div> | </div> | ||
| + | <br> | ||
| + | <br> | ||
| + | |||
</body> | </body> | ||
</html> | </html> | ||
| − | {{ | + | {{Northwestern_Page_Foot_temp}} |
Latest revision as of 17:09, 20 November 2017
Engineering pathways for integrating functional Cas9 protein into OMVs
Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.
-
About us
Northwestern University iGEM
LEARN MORE -
Project description
Outer Membrane Vesicles
LEARN MORE -
Parts
Cas9 fusion proteins
LEARN MORE
Project significance
VesiCure aims to create a therapeutic delivery system for CRISPR gene-editing technology using bacterial outer-membrane vesicles (OMVs). We hope to be able to utilize this delivery system to target the antibiotic resistant genes in bacteria, thereby allowing antibiotic treatments to be effective by eliminating the adaptive ability of bacterial resistance. By genetically altering the resistant bacteria, this treatment would help combat the problem of antibiotic resistance directly from the source.
